A New Hypothesis: The Immunomodulatory Effects of Mesenchymal Stromal Cell Derived Extracellular Vesicles in Ischemic Kidney Injury Partly through Spleen
Journal Title: Nephrology – Open Journal - Year 2015, Vol 1, Issue 2
Abstract
Ischemic Reperfusion Injury (IRI) is a major reason for Acute Kidney Injury (AKI) in hospitalization patients and could continue to result in end-stage kidney fibrosis. Mesenchymal Stromal Cells (MSCs) are regarded as a promising therapeutic method for AKI, but the potential ethical and tumorigenesis problems of MSCs limit clinical use. Recently Extracellular Vesicles (EVs) that contained in the MSCs’ condition medium were also found having a vital therapeutic effect in IRI induced AKI. As for the pluripotent prosperities of MSCs, MSC-EVs contain various bioactive substances that participate in the tissue repair and the immunomodulatory effect of MSC-EVs has been regarded as a crucial role in ischemic kidney injury and repair. However, the true mechanism still unknown. Based on existed facts, we hypothesized that the immunomodulatory effect of MSC-EVs in ischemic kidney injury partly through spleen.
Authors and Affiliations
Yingjian Zhu
Keywords
Related Articles
- EP ID EP558154
- DOI 10.17140/NPOJ-1-105
- Views 195
- Downloads 0
Recent Advances in Fibro-blast Growth Factor-23 Functions
During the past decade a lot of work has been done to better understand the roles of fibroblast growth factor-23 (FGF-23); a relatively newly discovered endocrine hormone, in multiple organ systems in the body. This revi...
Fibroblast Growth Factor 23 as a Therapeutic Target
This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibr...
Kidney Ischemia and Reperfusion Injury – Field of Glory or Warterloo for Erythropoietin?
When asking clinicians about their knowledge about Erythropoietin (EPO) most of them would say that it increases Red Blood Cell (RBC) count and can therefore be used to treat anemia, is produced in the kidneys and can be...
Review of the REPRISE Trial: Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
In the past, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and its Outcomes (TEMPO) trial showed Tolvaptan, a vasopressin V2-receptor antagonist, slowed the decline i...
Individualized Sodium Prescription in Hemodialysis: An Ally for Better Dialysis Outcomes?
The current practice in dialysis centres all over the world is to use standard sodium dialysate for all patients. Recently, there is a lot of interest in manipulating the dialysate sodium concentration to reduce fluid ov...